title: New Treatment Options for Patients With Metastatic Prostate Cancer: What Is The Optimal Sequence?
abstract: Systemic treatment of men with metastatic prostate cancer is rapidly evolving. Androgen deprivation therapy remains the first-line treatment for advanced disease and the backbone of sequential strategies. For patients with extensive metastatic disease the addition of docetaxel markedly improves survival. In case patients develop castration-resistant prostate cancer, several new therapeutic strategies are available. Large trials have shown a survival benefit for patients treated with sipuleucel-T, docetaxel, cabazitaxel, abiraterone, enzalutamide, or radium-223. Along with these new available treatment options, the sequence of applying them has become a serious matter of debate. In this review we provide an overview of current systemic treatment options for metastatic prostate cancer and propose considerations to optimally sequence registered new therapies. In addition, we hypothesize on improvement of outcome with potential combination strategies.
authors.affiliation: Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands.
authors.forename: Joyce M
authors.initials: JM
authors.lastname: van Dodewaard-de Jong
authors.affiliation: Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands.
authors.forename: Henk M W
authors.initials: HMW
authors.lastname: Verheul
authors.affiliation: Department of Medical Oncology, Meander Medical Center, Amersfoort, The Netherlands.
authors.forename: Haiko J
authors.initials: HJ
authors.lastname: Bloemendal
authors.affiliation: Department of Nuclear Medicine, Meander Medical Center, Amersfoort, The Netherlands.
authors.forename: John M H
authors.initials: JMH
authors.lastname: de Klerk
authors.affiliation: Johns Hopkins Kimmel Cancer Center, Baltimore, MD.
authors.forename: Michael A
authors.initials: MA
authors.lastname: Carducci
authors.affiliation: Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands. Electronic address: vandeneertwegh@vumc.nl.
authors.forename: Alfons J M
authors.initials: AJM
authors.lastname: van den Eertwegh
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary / Q000628:therapy*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D006801:Humans; D007167:Immunotherapy; D008297:Male; D011471:Prostatic Neoplasms / Q000473:pathology / Q000628:therapy*; D019275:Radiopharmaceuticals / Q000627:therapeutic use
chemical_list: D019275:Radiopharmaceuticals
keywords: Chemotherapy; Hormonal therapy; Immunotherapy; Prostate cancer; Radiopharmaceuticals